An abnormal metabolism of angiotensin II in essential hypertension has been suggested by several studies. Wood (1) reported that the venous blood of hypertensive patients showed a decreased capacity to inactivate an in vitro admixture with synthetic angiotensin' as judged by the pressor response on reinfusion into the hypertensive donors. Wolf and associates reported a prolonged radiochemical half-life of I131-labeled angiotensin in hypertensive patients after intravenous administration (2), but found a shortened radiochemical half-life in a purely in vitro system (3). Klaus (4) described a system in which the measurement of the amount of valine freed from synthetic valyl-5-angiotensin II after an in vitro admixture with plasma was equated to angiotensinase activity and reported no significant difference between hypertensive and normotensive plasma.
An abnormal metabolism of angiotensin II in essential hypertension has been suggested by several studies. Wood (1) reported that the venous blood of hypertensive patients showed a decreased capacity to inactivate an in vitro admixture with synthetic angiotensin' as judged by the pressor response on reinfusion into the hypertensive donors. Wolf and associates reported a prolonged radiochemical half-life of I131-labeled angiotensin in hypertensive patients after intravenous administration (2), but found a shortened radiochemical half-life in a purely in vitro system (3). Klaus (4) described a system in which the measurement of the amount of valine freed from synthetic valyl-5-angiotensin II after an in vitro admixture with plasma was equated to angiotensinase activity and reported no significant difference between hypertensive and normotensive plasma.
Thus, in the in vitro system employed, there has been suggested an increase, a decrease, and no change in the angiotensinase activity of the hypertensive plasma.2 Using the pressure response of the subject on reinfusion of an in vitro admixture leaves the difficult problem of controlling differences in vascular tone and reactivity between hypertensive and normotensive individuals. The t Career Development Award Program, U. S. Public Health Service grant HE-K-14,903-C1. 1 Ciba Pharmaceutical Co., Summit, N. J. 2 Plasma angiotensinase activity is used in this paper for convenience to designate the capacity of plasma to inactivate synthetic angiotensin, although a specific plasma enzyme, as such, has not been isolated to date. in vitro chemical methods leave the difficult problem of equating the chemical end-point to residual biological activity. It seemed that an in vitro system employing the loss of pressure response in a standard bioassay rat preparation to the serial injection of an admixture of plasma and angiotensin might obviate some of these difficulties and contribute to an understanding of this intricate problem.
MATERIALS AND METHODS
A. The assay. An in vitro admixture of synthetic angiotensin II 1 and plasma was studied for the progressive loss of pressor activity by serial inj ections into a 250-g vagotomized rat prepared with 'Nembutal and pentolinium. The left jugular vein was cannulated with polyethylene tubing and injected with a microsyringe containing a standard (1 /Ag per ml) dilution of angiotensin II (preserved as a 20%o ethanol solution). The right jugular vein was similarly connected to a microsyringe containing a mixture of 1 ml of the standard angiotensin solution and 1 ml of plasma. A stop watch was started at the time of the admixture, and room temperature was constant at 25 + 10 C. Alternate equal doses of standard angiotensin solution and standard solution mixed with plasma were administered every 3 to 4 minutes. The right carotid artery was cannulated with polyethylene tubing and the arterial pressure response recorded on a direct-writing pen-float mercury manometer. At the top of Figure 1 is shown the rat's pressure recording in a study on the plasma from a normotensive subject. The hatched spikes represent the serial pressure response of the plasma-angiotensin mixture and show the progressive reduction in the response; the nonhatched spikes represent the serial pressure response of the standard angiotensin solution alone and show full sensitivity of the rat to the serial injection of 10 m/Ag throughout the study. Variations, particularly a decrease of the standard response by more than 2 Figure 5) .
B. Renal hypertension. Figure 6 shows the results for the 4 groups with renal hypertension in comparison with the normal. Unilateral pyelonephritis 35 14 7.0 >.2 <.4 30 7 Chronic glomerulonephritis during the first trimester. All 5 values for plasma angiotensinase activity were considerably above the normal range (+ 78 to + 148%), with a mean activity that was 148% above the normal mean. The difference in the mean from the normal mean for the 20-minute percentage of destruction was highly significant (p <.001).
The angiotensinase activity data for all groups studied are summarized in Table IV . DISCUSSION Our working hypothesis has been that states which may have in common an underlying increased rate of angiotensin elaboration, with or without hypertension, may develop an increased plasma capacity to inactivate angiotensin through a process of substrate induction, that is, through a specific enzymatic adaptation at the cellular level. Knox, Auerbach, and Lin (10) have reviewed the subject of enzymatic adaptation, citing animal work in which amino acid oxidase activity increased in response to the administration of protein and specific amino acids. Whether the angiotensinase activity in plasma is represented by a single specific protease or several has not been established as yet. Since a variety of highly purified proteolytic enzymes have the capacity of inactivating angiotensin (5), the degree of specificity of plasma angiotensinase activity will have to await the isolation of such activity from the plasma proteins. Other possibilities exist, such as the elaboration of specific angiotensinase inhibitors or activators to account for-the observed alterations in plasma angiotensinase activity.
The 4 groups of patients with hypertension that demonstrated a significant elevation in plasma angiotensinase activity were 1) those with essential hypertension that had progressed to a stage of hypertensive cardiovascular disease of-a moderate to severe degree, 2) those with hypertension related to chronic glomerulonephritis, particularly in its advanced stages, 3) those with hypertension related to renal artery stenosis, and 4) the 2 patients with pheochromocytoma. No significant change was found in the group with hypertension associated with chronic pyelonephritis and unilateral pyelonephritis, irrespective of the severity of the hypertensive disease. Thus, the group with chronic bilateral pyelonephritis serves as a sick control group, where no elevation of angiotensinase activity was found, despite the presence of uremia in 7 of the 9 patients, 3 of whom had the changes of malignant hypertension and were studied shortly before their death. One uremic pa-tient with an elevated angiotensinase activity associated with chronic glomerulonephritis and hypertension had no change in his angiotensinase activity after hemodialysis, despite a marked reduction in his blood urea nitrogen concentration.
There is a striking correlation between these findings and the degree of juxtaglomerular hypertrophy as determined by juxtaglomerular cell counts, reported by Turgeon and Sommers (11) . These workers reported juxtaglomerular hyperplasia in the same 4 hypertensive groups in which a significant increase in plasma angiotensinase activity is reported here (essential hypertension, chronic glomerulonephritis, renal artery stenosis, and pheochromocytoma). Further, they failed to find hyperplasia in the pyelonephritic group with hypertension. corresponding with the lack of a significant increase in plasma angiotensinase activity reported here. The evidence that the renin secretory mechanism is situated in the juxtaglomerular apparatus has been reviewed by Tobian (12) and is substantial; it is assumed that a high rate of renin secretion may be associated with a high rate of angiotensin elaboration (13) .
Although a modest elevation of angiotensin blood levels in humans with severe essential hypertension has been reported in the past (14) , Genest and co-workers, employing a more specific method (15) , found an elevation in only 30% of their determinations (16) . There is more uniform agreement on a consistent elevation in the renal vein blood in hypertension due to renal artery stenosis (17. 18) . Angiotensin data in hypertension associated with chronic nephritis and pheochromocytoma are not as yet available. The failure to show consistently elevated blood angiotensin levels in essential hypertension in no way precludes the possibility of an elevated rate of elaboration, particularly in the more advanced stages of the disease, in the light of the finding of a progressive elevation in plasma angiotensinase activity as the disease advances, which would tend to mask such a phenomenon. It This leads to the question of the mechanism of the hypertension in the group with chronic pyelonephritis, where juxtaglomerular hypertrophy and elevated plasma angiotensinase activity are strikingly absent. Assuming a predominantly renal medullary destruction in this disease, one may speculate that this represents a human manifestation of renoprival hypertension as suggested by several studies (20, 21) , where a protecting, antihypertensive medullary factor, as identified by Muirhead, Jones, and Stirman (22) , may have been eliminated by the disease. Although a figure is hard to arrive at, a significant reduction of pressure following extirpation of a unilaterally pyelonephritic kidney may be expected in "less than half of such cases" (23) , whereas a significant improvement in the range of 75% has been reported (24) following surgery for occlusive renal arterial disease. However, one must account for those isolated reports of definite improvement following excision of a unilaterally pyelonephritic kidney (25) . In this regard it is of interest that, although the mean angiotensinase level was not significantly elevated above the normal mean, 2 of the 4 cases of unilateral pyelonephritis had a level above the normal range. A renal pressor mechanism may be contributing to the hypertension in certain instances of pyelonephritis through a process of proliferative endarteritis, as emphasized by Smythe (26) . Saphir (27) proposes the existence of 2 types of pyelonephritis, one being clinically evident with the predominant feature of medullarv destruction, and the other, "pyelonephritis lenta," being clinically silent with a prominent feature of vascular intimal fibrosis and hyalinization leading to hypertension (and often misdiagnosed as essential hypertension). Sommers (21) on the basis of juxtaglomerular cell counts, states that "pyelonephritis that causes an intrarenal Goldblatt-type phenomenon does occur but it is relatively rare in the material analyzed so far." If the plasma angiotensinase level proves to be differentiating, a greater degree of sophistication may be obtained in the surgical selection of those patients with hypertension associated with unilateral renal disease. The degree of surgical success may be proportional to the degree to which the renal pressor mechanism is responsible for the hypertension.
The common denominator for those instances of an elevated plasma angiotensinase activity in the various hypertensive groups may prove to be a renal pressor mechanism resulting from extrinsic or intrinsic renovascular disease. This may be either a cause or a consequence of the elevated arterial pressure. In pheochromocytoma, persistent renal vasoconstriction may be sufficient to account for the mechanism, even in the absence of nephrosclerosis.
In a recent review, Davis, Carpenter, and Ayers (28) have summoned -up convincing evidence for the role of the renin-angiotensin system in the control of aldosterone secretion. It is of interest that Laragh (29) found elevated aldosterone secretory rates in the advanced and particularly the malignant phase of essential hypertension, but not in the milder stages. This report is quite parallel to the plasma angiotensinase data presented above. If an angiotensinemia is assumed to apply in general to clinical states associated with secondary hyperaldosteronism, it seemed reasonable to look for an elevated angiotensinase activity in patients with refractory edema and pregnancy. As cited above, the highest mean levels observed for plasma angiotensinase activity were found in these conditions. The absence of hypertension in these groups (excepting the toxemic patients), does not preclude the possibility of an increased rate of angiotensin elaboration in the light of Laragh's finding (30) of a refractoriness to the pressor effects of infused angiotensin in cirrhotic patients with ascites. The finding of hypergranulation of the juxtaglomerular cells from kidneys of sodium deficient rabbit (31) , of dogs with hyperaldosteronism secondary to thoracic caval construction (32) , and of rats with experimental nephrosis (33) is supportive evidence. If Tobian's view (12) that the juxtaglomerular cells act as stretch receptors is sustained, then the common denominator between hypertension associated with renal vascular disease on the one hand and edematous states on the other for the activation of the renin-angiotensin-aldosterone system would be a decreased renal perfusion pressure, whether through a vascular obstruction at the renal level or through the sequestration of effective circulating volume as edema fluid. Such a contraction of plasma volume has been determined in the nephrotic syndrome and cirrhosis with ascites; in severe congestive failure the redistribution of blood on the venous side of the circulation has the same effect (34) . In pregnancy, however, cardiac output and renal blood flow are increased until week 32 except in severe pre-eclampsia (35) , and in this situation this line of reasoning cannot be applied. The possibility exists that an unidentified placental factor may be operative in activating the renin mechanism to meet the need for a positive sodium balance during pregnancy. An increase in plasma oxytocinase activity at term is another possibility.
The finding of an elevated angiotensinase activity in an undertreated patient with Addison's disease is probably indicative of an activation of the renal pressor system due to volume depletion, comparable to the observations in hemorrhagic shock (36) . Experimental support is offered by the observation of increased juxtaglomerular granularity in the adrenalectomized cat (37) . The finding of a normal level in 2 patients with hypertension secondary to Cushing's syndrome suggests that the assay may be helpful in identifying forms of secondary hypertension where the renal pressor system is not involved.
It is hypothesized than angiotensinemia and hyperaldosteronism may only develop in those conditions where an increased rate of angiotensin elaboration exceeds an adaptive increase in the rate of angiotensin destruction.
The authors are aware that there may be other disease states not associated with hypertension or edema which may also prove to have alterations in the plasma angiotensinase activity. Any profound disturbance in the plasma proteins and alteration in circulating proteases such as may at-tend severe pancreatic or hepatobilary disease carries with it this potential. A systematic appraisal will be a subject for further investigation. SUMMARY 1) An in vitro biological method for the determination of plasma angiotensinase activity is described. Plasma angiotensinase activity is used for convenience to designate the capacity of plasma to inactivate synthetic angiotensin, although a specific plasma enzyme, as such, has not been isolated to date.
2) A significant elevation was found in the following hypertensive disorders: essential hypertension complicated by moderately severe to severe hypertensive cardiovascular disease, chronic glomerulonephritis, occlusive renal arterial disease, and pheochromocytoma.
3) Evidence is cited from the literature for the increased activity of the renin secretory mechanism in each of these diseases, which may have in common an ischemic or obstructive renal vascular disorder.
4) In the two groups with conditions commonly associated with secondary hyperaldosteronism, refractory edema and pregnancy (normal and abnormal), marked elevations of plasma angiotensinase activity were also found.
5) It is suggested that the increased plasma angiotensinase activity in these states may ensue from an increased rate of angiotensin elaboration through a process of enzymatic adaptation. 6) In the light of these findings, reports of the failure to find a consistently elevated blood angiotensin level in even the more severe stages of essential hypertension and in malignant hypertension do not preclude the possibility of an increased rate of angiotensin elaboration.
